Last updated: June 8, 2026
CMP Development, LLC v. Amneal Pharmaceuticals LLC, No. 1:21-cv-00549 (D. Del.), is a U.S. patent infringement case tied to Amneal’s FDA generic development of a CMP Development–patented pharmaceutical product. The action is filed as part of the Hatch-Waxman framework and is aimed at blocking or narrowing Amneal’s market entry based on asserted Orange Book-listed patent rights.
What patents are at issue? The patent(s) and claims at issue are not provided in the input, so this litigation summary cannot accurately identify the specific asserted patents, expiration dates, claim scope, or which Orange Book listings triggered the dispute.
What is CMP Development, LLC v. Amneal Pharmaceuticals LLC | 1:21-cv-00549 about?
Core dispute: CMP Development alleges Amneal infringes one or more patents listed for a branded reference drug in the FDA Orange Book, typically after Amneal makes a Paragraph IV certification (or related certification) when seeking FDA approval for a generic version.
Case posture (what this usually means procedurally in Hatch-Waxman):
- Filing by a patent holder to enforce exclusivity against a would-be generic entrant.
- Assertions framed around one or more patents covering the reference-listed drug product (drug substance, composition, formulation, method-of-use, or other protected subject matter).
- Potential outcomes include a merits judgment on infringement and validity, a stipulation/settlement, or a dismissal.
Key business implication: The case determines whether Amneal can launch before patent expiry, and it can narrow design-around options if the asserted claims are broad and cover composition, formulation, or use.
Which patents and claims did CMP Development assert in 1:21-cv-00549?
Not available in the provided input.
A litigation-grade analysis requires at minimum:
- asserted patent numbers,
- asserted independent and dependent claim numbers,
- accused product(s) and dosage forms,
- the infringement theory (composition, method-of-use, manufacturing, etc.),
- the validity defenses and claim construction positions.
Without those specifics, any attempt to state “what patents protect” the product or “how strong” the estate is would be speculative and not litigation-usable.
What is the procedural timeline for 1:21-cv-00549 (filing, motions, hearings, outcome)?
Not available in the provided input.
A complete litigation summary should include:
- complaint filing date,
- answer and any counterclaims,
- claim construction schedule (Markman),
- dispositive motions (12(b)(6), summary judgment),
- trial dates (if set),
- any stipulation of dismissal or final judgment date.
The input does not include docket dates or outcomes, so a timeline cannot be provided without risking factual errors.
What is the court and jurisdiction for CMP Development v. Amneal (D. Del.) and what does that imply?
Court: U.S. District Court for the District of Delaware.
Delaware is a primary Hatch-Waxman venue due to established patent practice, predictable scheduling, and frequent use of magistrate-judge referral for claim construction and pretrial management.
What this implies for litigation strategy (high level):
- Early claim construction is often pivotal for infringement and validity.
- Delaware judges commonly enforce tight procedural deadlines, making motion practice and expert alignment decisive.
How do Paragraph IV certifications connect to this case?
Typical Hatch-Waxman linkage:
A Paragraph IV certification by Amneal against CMP Development’s Orange Book patents usually triggers:
- a 45-day notice,
- a lawsuit within statutory timelines (commonly within the 45-day window, measured from notice to the NDA holder/patent owner),
- an automatic 30-month stay of FDA approval (subject to statutory exceptions and litigation outcomes).
Outcome impacts:
- If CMP Development prevails on infringement and/or validity, Amneal launch is blocked until the patents expire.
- If CMP Development fails, Amneal may launch immediately (subject to other listed patents or exclusivity).
What is the infringement theory in CMP Development v. Amneal?
Not available in the provided input.
A proper infringement analysis depends on:
- accused Amneal product formulation or method steps,
- claim elements CMP Development alleges are met,
- expert reports for claim chart mapping,
- claim construction rulings (often determinative).
Without the asserted claims and infringement contentions, the infringement theory cannot be described accurately.
What validity arguments did CMP Development and Amneal raise (101, 102, 103, 112) and how strong are they?
Not available in the provided input.
A validity/strength analysis must map:
- novelty and anticipation references,
- obviousness combinations,
- enablement and written description,
- indefiniteness,
- claim scope limits from construction.
The input provides no invalidity contentions, no prior art list, and no claim construction decisions.
What does the claim construction likely control in a Hatch-Waxman case like this?
General control points (not case-specific):
- The meaning of key claim terms defines whether the accused formulation or use literally infringes.
- Construction also shapes infringement doctrine under equivalents and can narrow or broaden validity exposure.
- Product-specific parameters (e.g., active ingredient concentration, excipient set, polymorph/solid state, release profile) are often where the factual and technical battle is concentrated.
Did the case end in settlement, dismissal, or a final judgment?
Not available in the provided input.
Settlement and dismissal outcomes are common in Orange Book patent disputes, often paired with:
- a confidential license,
- a covenant not to sue,
- an agreed design-around,
- an agreed launch date,
- or partial dismissals based on narrowed claim scope.
A litigation summary must include the actual disposition to be decision-grade.
What is the FDA launch risk for Amneal based on this case?
Not available in the provided input.
Launch risk assessment requires:
- which patents were asserted,
- the current status of those patents (expiration dates, terminal disclaimers),
- whether those patents were found invalid/unenforceable or not infringed,
- whether a settlement removed the barrier.
Without the asserted patent numbers and any outcome, no correct launch-risk ranking can be given.
What is the Orange Book status of the asserted patents in 1:21-cv-00549?
Not available in the provided input.
To answer this, the article needs:
- reference listed drug (RLD) name,
- Orange Book NDA number,
- patent list entries (drug substance, drug product, method-of-use),
- expiration dates and remaining regulatory exclusivity.
The input provides none of these details.
Which companies were parties beyond CMP Development and Amneal, and are there co-defendants?
Not available in the provided input.
Hatch-Waxman suits sometimes include:
- generic applicants and related distributors,
- manufacturing entities,
- corporate affiliates,
- and in rare cases additional defendants tied to ANDA manufacturing or labeling.
No party list is provided.
What design-around options exist if CMP Development’s claims are broad?
Not case-specific.
Design-around possibilities depend on what the asserted claims cover:
- composition claims can sometimes be avoided by changing formulation/excipients or solid-state form,
- method-of-use claims can sometimes be avoided by altering prescribing instructions, patient population, or dosing regimen,
- manufacturing-method claims can sometimes be avoided by changing process parameters.
Because the asserted claim scope is not stated, design-around analysis cannot be stated reliably.
How does this case compare with other CMP Development v. generic entrants in the same portfolio?
Not available in the provided input.
A comparison requires:
- a list of CMP Development’s other relevant Hatch-Waxman disputes,
- outcomes and patent families,
- recurring asserted claims and frequently used prior art.
No cross-case data is provided.
Key Takeaways
- Case identity: CMP Development, LLC v. Amneal Pharmaceuticals LLC, No. 1:21-cv-00549 (D. Del.), is a Hatch-Waxman style patent infringement dispute tied to an Orange Book patent barrier against Amneal’s generic approval path.
- Decision-grade gaps: The input does not include the asserted patent numbers, claim scope, docket timeline, or final disposition, so no accurate patent-expiration, infringement, validity, or launch-risk conclusions can be provided.
- Business impact (framework level): The case outcome typically determines whether Amneal’s launch is blocked, delayed, or permitted via a settlement or merits ruling.
FAQs
- What is the statutory basis for automatic stays in Hatch-Waxman cases like 1:21-cv-00549?
- How do claim construction rulings typically change infringement outcomes in Orange Book patent cases?
- What settlement terms are most common in CMP Development-style Orange Book disputes (license, covenant not to sue, launch-date agreements)?
- How should an ANDA sponsor evaluate the remaining patent landscape after a dismissal or partial invalidity finding?
- What labeling or “skinny label” strategies can reduce method-of-use infringement risk in paragraph IV disputes?
References
- No case docket, complaint, Orange Book listing, court order, or opinion text was provided in the input.
